Kliniska studier för Mani i Kalifornien
5 studier för Mani söker deltagare vid platser i Kalifornien.
Städer i Kalifornien
Officiell studietext (engelska)
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
- Neurocrine Clinical Site, Cerritos
- Neurocrine Clinical Site, Garden Grove
- Neurocrine Clinical Site, San Diego
RekryterarFas 2
Ålder 18 till 65 · Alla kön · Uppdaterad 29 sep. 2026 · NCT07288320A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
- Proscience Research Group, Culver City
- Clinical Innovations, Inc. dba CITrials, Riverside
- Collaborative Neuroscience Research, LLC, Torrance
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 24 sep. 2026 · NCT06951711A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
- Advanced Research Center Inc., Anaheim
- CITrials, Bellflower
- Local Institution - 0014, Cerritos
- och 3 fler
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 22 sep. 2026 · NCT06951698A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
- Advanced Research Center Inc., Anaheim
- Clinical Innovations, Inc. dba CITrials, Bellflower
- Local Institution - 0044, Cerritos
- och 10 fler
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 14 sep. 2026 · NCT06929273A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
- Clinical Innovations, Inc. dba CITrials, Bellflower
- Inland Psychiatric Medical Group., Chino
- Proscience Research Group, Culver City
- och 4 fler
RekryterarFas 3
Ålder 18 till 65 · Alla kön · Uppdaterad 23 juni 2026 · NCT07140913Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.